6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For
the
month of March, 2006.
Commission
File Number ________________
Novogen
Limited
(Translation
of registrant’s name into English)
140
Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F
x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o No
o
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
82-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Novogen
Limited
(Registrant)
/s/
Ron Erratt
Ronald
Lea Erratt
Company
Secretary
Date
31 March, 2006
ASX
& MEDIA RELEASE
31
MARCH 2006
Novogen
Limited’s subsidiary, Marshall Edwards Inc. (NASDAQ: MSHL), has just made the
following announcement:
MSHL
ANNOUNCEMENT
Marshall
Edwards Inc (NASDAQ:MSHL) will be presenting at the CIBC World Markets Annual
Biotechnology and Specialty Pharmaceuticals Conference on Tuesday April
4, 2006.
The
presentation at the Millennium Broadway, New York City will be at 8.30am
and
webcast on http://www.veracast.com/webcasts/cibcwm/biotech06/62101372.cfm
About
Marshall Edwards:
Marshall
Edwards, Inc. (Nasdaq : MSHL) has licensed rights from Novogen Limited (Nasdaq
:
NVGN) to bring phenoxodiol to market globally. Marshall Edwards, Inc. is
majority owned by Novogen, an Australian biotechnology company that is
specializing in the development of therapeutics based on regulation of the
sphingomyelin pathway. Novogen, based in Sydney, Australia, is developing
a
range of therapeutics across the fields of oncology, cardiovascular disease
and
inflammatory diseases.
More
information on phenoxodiol and on the Novogen group of companies can be found
at
www.marshalledwardsinc.com
and
www.novogen.com.
ISSUED
FOR : NOVOGEN
LIMITED
LISTINGS : ASX
(CODE NRT), NASDAQ (CODE NVGN).
FOR
FURTHER
INFORMATION : CHRISTOPHER
NAUGHTON, MANAGING DIRECTOR, NOVOGEN LIMITED
TEL
(02) 9878 0088 http://www.novogen.com
ISSUED
BY : WESTBROOK
COMMUNICATIONS
CONTACT:
DAVID REID TEL (02) 9231 0922 OR 0417 217 157